Deciphera Pharmaceuticals, Inc.
DCPHNASDAQHealthcare
$25.59
+$0.02(+0.08%)
Market Cap$2.2B
P/E Ratio—
52W High$25.61
52W Low$9.9
Deciphera Pharmaceuticals, Inc. (DCPH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DCPH · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2024Report Date: May 10, 2024EPS Actual
-$0.52
Est. -$0.55 · +5.5%
Revenue
$0.04B
Est. $0.05B · -2.8%
Fiscal Period
Q2 FY2024
FY ends December
Report Date
May 10, 2024
After Market Close
▲ Beat EPS▼ Miss Revenue🔥 5-Quarter EPS Beat Streak
DCPH reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.59B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.59B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q2 FY2024 | May 10, 2024 | -$0.55 | -$0.52 | +5.5% | $0.04B | $0.05B | -2.8% |
| ▲ Q1 FY2024 | Feb 6, 2024 | -$0.58 | -$0.54 | +6.9% | $0.05B | $0.05B | +5.2% |
| ▲ Q4 FY2023 | Oct 30, 2023 | -$0.60 | -$0.58 | +3.3% | $0.04B | $0.04B | +10.1% |
| ▲ Q3 FY2023 | Aug 9, 2023 | -$0.62 | -$0.57 | +8.1% | $0.04B | $0.04B | +6.8% |
| — Q2 FY2023 | May 3, 2023 | -$0.60 | -$0.60 | +0.0% | $0.03B | $0.04B | -6.6% |
| ▼ Q1 FY2023 | Feb 7, 2023 | -$0.57 | -$0.60 | -5.3% | $0.04B | $0.04B | +1.0% |
| ▲ Q4 FY2022 | Nov 3, 2022 | -$0.57 | -$0.55 | +3.5% | $0.04B | $0.03B | +8.7% |
| ▲ Q3 FY2022 | Aug 4, 2022 | -$0.65 | -$0.60 | +7.7% | $0.03B | $0.03B | +6.3% |
Q2 FY2024
May 10, 2024Beat
EPS Actual
-$0.52
EPS Est.
-$0.55
EPS Surpr.
+5.5%
Revenue
$0.04B
Q1 FY2024
Feb 6, 2024Beat
EPS Actual
-$0.54
EPS Est.
-$0.58
EPS Surpr.
+6.9%
Revenue
$0.05B
Q4 FY2023
Oct 30, 2023Beat
EPS Actual
-$0.58
EPS Est.
-$0.60
EPS Surpr.
+3.3%
Revenue
$0.04B
Q3 FY2023
Aug 9, 2023Beat
EPS Actual
-$0.57
EPS Est.
-$0.62
EPS Surpr.
+8.1%
Revenue
$0.04B
Q2 FY2023
May 3, 2023
EPS Actual
-$0.60
EPS Est.
-$0.60
EPS Surpr.
+0.0%
Revenue
$0.03B
Q1 FY2023
Feb 7, 2023Miss
EPS Actual
-$0.60
EPS Est.
-$0.57
EPS Surpr.
-5.3%
Revenue
$0.04B
Q4 FY2022
Nov 3, 2022Beat
EPS Actual
-$0.55
EPS Est.
-$0.57
EPS Surpr.
+3.5%
Revenue
$0.04B
Q3 FY2022
Aug 4, 2022Beat
EPS Actual
-$0.60
EPS Est.
-$0.65
EPS Surpr.
+7.7%
Revenue
$0.03B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.31 | $-0.31 | $-0.31 | 2 |
| Q3 FY2025 | $-0.42 | $-0.42 | $-0.42 | 2 |
| Q2 FY2025 | $-0.47 | $-0.47 | $-0.47 | 2 |
| Q1 FY2025 | $-0.50 | $-0.50 | $-0.50 | 2 |
| Q4 FY2024 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Q3 FY2024 | $-0.60 | $-0.50 | $-0.39 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2025 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2025 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2025 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2024 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2024 | $0.0B | $0.1B | $0.1B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2024 | May 10, 2024 | +5.5% | $25.37 | $25.36 | -0.04% |
| ▲ Q1 FY2024 | Feb 6, 2024 | +6.9% | $14.76 | $14.83 | +0.47% |
| ▲ Q4 FY2023 | Oct 30, 2023 | +3.3% | $10.15 | $11.93 | +17.54% |
| ▲ Q3 FY2023 | Aug 9, 2023 | +8.1% | $12.94 | $13.74 | +6.18% |
| ▲ Q2 FY2023 | May 3, 2023 | +0.0% | $14.30 | $13.93 | -2.59% |
| ▼ Q1 FY2023 | Feb 7, 2023 | -5.3% | $16.71 | $16.58 | -0.78% |
| ▲ Q4 FY2022 | Nov 3, 2022 | +3.5% | $16.64 | $16.43 | -1.26% |
| ▲ Q3 FY2022 | Aug 4, 2022 | +7.7% | $13.57 | $16.81 | +23.88% |
Q2 FY2024-0.04%
Report Date
May 10, 2024
EPS Beat/Miss
+5.5%
Price Before
$25.37
Price After
$25.36
Q1 FY2024+0.47%
Report Date
Feb 6, 2024
EPS Beat/Miss
+6.9%
Price Before
$14.76
Price After
$14.83
Q4 FY2023+17.54%
Report Date
Oct 30, 2023
EPS Beat/Miss
+3.3%
Price Before
$10.15
Price After
$11.93
Q3 FY2023+6.18%
Report Date
Aug 9, 2023
EPS Beat/Miss
+8.1%
Price Before
$12.94
Price After
$13.74
Q2 FY2023-2.59%
Report Date
May 3, 2023
EPS Beat/Miss
+0.0%
Price Before
$14.30
Price After
$13.93
Q1 FY2023-0.78%
Report Date
Feb 7, 2023
EPS Beat/Miss
-5.3%
Price Before
$16.71
Price After
$16.58
Q4 FY2022-1.26%
Report Date
Nov 3, 2022
EPS Beat/Miss
+3.5%
Price Before
$16.64
Price After
$16.43
Q3 FY2022+23.88%
Report Date
Aug 4, 2022
EPS Beat/Miss
+7.7%
Price Before
$13.57
Price After
$16.81
Avg Beat Reaction+6.31%
Avg Miss Reaction-0.78%
Beat Rate7 / 8 quarters
Largest Move+23.88% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DCPH ends December
Deciphera Pharmaceuticals, Inc. (DCPH) most recently reported earnings on May 10, 2024 for Q2 FY2024, posting EPS of $-0.52 — beating the analyst consensus of $-0.55 by +5.5%. DCPH has beaten EPS estimates for 5 consecutive quarters. The next DCPH earnings date is expected around September 1, 2026.
Each quarter, investors track DCPH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DCPH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DCPH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DCPH earnings · 5 questionsDeciphera Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. DCPH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DCPH historically reports after market close (AMC).
DCPH earnings datewhen is DCPH earningsDCPH next earnings datewhen does DCPH report earningsDCPH earnings calendar
▸ Source: FMP · Deciphera Pharmaceuticals, Inc. SEC filings · US GAAP · Deciphera Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026